ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J. Souers, Steven W. Elmore, Lloyd T. Lam et al.|Nature Medicine|2013Cited by 3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaAndrew W. Roberts, John F. Seymour, Matthew S. Davids et al.|New England Journal of Medicine|2015Cited by 1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S. Davids, John F. Gerecitano, Andrew W. Roberts et al.|Journal of Clinical Oncology|2017Cited by 752
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell LymphomaConstantine S. Tam, Andrew W. Roberts, Mary Ann Anderson et al.|New England Journal of Medicine|2018Cited by 429
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLLConstantine S. Tam, Andrew W. Roberts|Blood|2019Cited by 366